Based on the results of DEN+HFMCD versus DEN+HFD, the DEN+HFMCD model was selected and an anti-IL-17A treatment window was determined from 6 weeks to 16 weeks to assess its effect on NASH-HCC transition and HCC progression. The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatohepatitis.